Hepatic EncephalopathyPhase 1/2NCT03439982
Fecal Transplant for Hepatic Encephalopathy
A Phase 1/2 study testing FMT in people with Hepatic Encephalopathy, run by University of Alberta at 1 site in Canada.
Trial summary
The purpose of the study is to determine if fecal microbiota transplant (FMT) can reverse hepatic encephalopathy (HE) in cirrhotic patients who continue to have breakthrough episodes of HE despite maintenance therapy with lactulose and/or rifaximin or metronidazole. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hepatic Encephalopathy
- What is being tested?
- FMT
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 3 participants
- Where
- 1 siteCanada
- Study dates
- 12 Apr 2016to 18 Mar 2021
- Phase
- Phase 1/2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adult cirrhotic patients of various etiology on lactulose and/pr rifaximin or metronidazole for minimum 4 weeks as secondary prophylaxis
- Abnormal ICT (>5 lures) or abnormal Stroop test (>200 seconds)
- Baseline Conn score 0 or 1
- Infectious etiology of HE has been ruled out
Who cannot join
- those with tense ascites
- those who do not provide assent
- life expectancy <3 months
- TIPS within the past 3 months
- neurologic disease such as dementia, Parkinson's, structural brain lesions
- pregnancy
Show all 15Show fewer
- intestinal obstruction
- alcoholic hepatitis
- active alcohol or substance abuse
- those without stable social support
- concurrent infection such as spontaneous bacterial peritonitis, pneumonia or urinary tract infection
- creatinine clearance less that 50% compared to baseline
- hospital admission for HE within one month of enrollment
- active hepatocellular carcinoma
- active GI bleed
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Prospective Single Center Open Label Trial of RBX2660 (Microbiota Suspension) in the Management of Hepatic Encephalopathy
The purpose of the study is to determine if fecal microbiota transplant (FMT) can reverse hepatic encephalopathy (HE) in cirrhotic patients who continue to have breakthrough episodes of HE despite maintenance therapy with lactulose and/or rifaximin or metronidazole.
Read the detailed description
Subjects receive FMT from a single donor by colonoscopy at week 0 and by enema at weeks 1-4. HE is measured by Inhibitory Control Test (ICT) and Stroop test as well as fasting serum ammonia levels.
- Conditions
- Hepatic Encephalopathy
- Being tested
- FMT
- Keywords
- Hepatic encephalopathy, fecal microbiota transplant
- Medical subject headings
- Hepatic Encephalopathy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
FMTBiological
FMT processed from routinely screened donors
| Study group | Role | What they receive |
|---|---|---|
| FMT | Experimental | Open label FMT administered at week 0 by colonoscopy and weeks 1-4 by enema Receives: Biological: FMT |
What is being measured
The primary outcome is the main question the study is designed to answer.
Portion of participants with normalization of ICT or Stroop Test during the study
Measured: 8 weeks
Secondary outcomes (7)
Proportion of patients with normalization ICT or Stroop test scores at 1 week, 2 weeks, 4 weeks and 8
Measured: 8 weeks
Changes in serum ammonia level pre and post FMT
Measured: 8 weeks
Changes in Quality of Life measured by Chronic Liver Disease Questionnaire (CDLQ) pre and post FMT
29 Questions Total- each question is on a seven point scales, ranging from the worst (1) to the best (7) possible function
Measured: 8 weeks
Change in Intestinal Microbiota pre-and post FMT
Measured: 8 weeks
Serious Adverse Events
- All serious adverse events up to and including week 8. A serious adverse event is any event which results in any of the following: i) Death ii) Colonic perforation iii) Proven infections as defined by the presence of i) spontaneous bacteremia: positive blood cultures in the absence of any other potential source of infection; ii) spontaneous bacterial peritonitis: ascetic fluid PMN equal to or greater than 250/mm3; iii) UTI: urinary leukocyte count greater than 15 cells per HPF and positive urine culture; vi) other infections identified by clinical, radiologic and bacteriologic results. iv) Possible infections as defined by i) fever (temp > 37.80 C), ii) leukocytosis (>15,000 mm3) or increased immature neutrophils in blood (>500 mm3), negative cultures and no other signs of infection.
Measured: 8 weeks
Change in stool Bile Acids Composition pre and post FMT
Measured: 8 Weeks
Changes in stool short chain free fatty acids pre and post FMT
Measured: 8 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Feb 2018
- Study start12 Apr 2016
- Primary completion7 Aug 2019
- Study completion18 Mar 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Hepatic EncephalopathyStudies of the same condition, open and under way.
- More trials run by University of AlbertaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 3 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Alberta
- Sponsor type
- University, hospital or other
- Collaborators
- Rebiotix Inc.
- Responsible party
- Sponsor
- Investigators
- Dina Kao, MD, Principal investigator, Associate Professor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03439982
- Sponsor's protocol ID
- Pro00060782
- Status last verified
- Jul 2021
- First submitted
- 13 Feb 2018
- Last updated
- 10 Jun 2022
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Pun CK, Huang HC, Chang CC, Hsu SJ, Huang YH, Hou MC, Lee FY. Hepatic encephalopathy: From novel pathogenesis mechanism to emerging treatments. J Chin Med Assoc. 2024 Mar 1;87(3):245-251. doi: 10.1097/JCMA.0000000000001041. Epub 2023 Dec 18.
PubMed 38109364
Study at a glance
From the registry record, last updated by the sponsor on 10 Jun 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective Single Center Open Label Trial of RBX2660 (Microbiota Suspension) in the Management of Hepatic Encephalopathy
- ClinicalTrials.gov ID
- NCT03439982
- Acronym / sponsor ID
- Pro00060782
- Conditions
- Hepatic Encephalopathy
- Keywords
- Hepatic encephalopathy, fecal microbiota transplant
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 3 participants (actual)
- Lead sponsor
- University of AlbertaUniversity, hospital or other
- Collaborators
- Rebiotix Inc.
- Study start
- 12 Apr 2016 (actual)
- Primary completion
- 7 Aug 2019 (actual)
- Study completion
- 18 Mar 2021 (actual)
- First posted
- 20 Feb 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of the study is to determine if fecal microbiota transplant (FMT) can reverse hepatic encephalopathy (HE) in cirrhotic patients who continue to have breakthrough episodes of HE despite maintenance therapy with lactulose and/or rifaximin or metronidazole.
Detailed description
Subjects receive FMT from a single donor by colonoscopy at week 0 and by enema at weeks 1-4. HE is measured by Inhibitory Control Test (ICT) and Stroop test as well as fasting serum ammonia levels.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| FMT | Experimental | Biological: FMTOpen label FMT administered at week 0 by colonoscopy and weeks 1-4 by enema |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Adult cirrhotic patients of various etiology on lactulose and/pr rifaximin or metronidazole for minimum 4 weeks as secondary prophylaxis
- Abnormal ICT (>5 lures) or abnormal Stroop test (>200 seconds)
- Baseline Conn score 0 or 1
- Infectious etiology of HE has been ruled out
Key exclusion criteria (15 listed)
- those with tense ascites
- those who do not provide assent
- life expectancy <3 months
- TIPS within the past 3 months
- neurologic disease such as dementia, Parkinson's, structural brain lesions
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| FMTFMT processed from routinely screened donors | Biological | FMT |
Primary outcome
Portion of participants with normalization of ICT or Stroop Test during the study
Time frame: 8 weeks
7 secondary outcomes
Proportion of patients with normalization ICT or Stroop test scores at 1 week, 2 weeks, 4 weeks and 8
Time frame: 8 weeks
Changes in serum ammonia level pre and post FMT
Time frame: 8 weeks
Changes in Quality of Life measured by Chronic Liver Disease Questionnaire (CDLQ) pre and post FMT
Time frame: 8 weeks
Change in Intestinal Microbiota pre-and post FMT
Time frame: 8 weeks
Serious Adverse Events
Time frame: 8 weeks
Change in stool Bile Acids Composition pre and post FMT
Time frame: 8 Weeks
Changes in stool short chain free fatty acids pre and post FMT
Time frame: 8 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Jun 2022.
- Derived from this study: PubMed 38109364Pun CK, Huang HC, Chang CC, Hsu SJ, Huang YH, Hou MC, Lee FY. Hepatic encephalopathy: From novel pathogenesis mechanism to emerging treatments. J Chin Med Assoc. 2024 Mar 1;87(3):245-251. doi: 10.1097/JCMA.0000000000001041. Epub 2023 Dec 18.
- Individual participant dataSharing planned: No
Related trials for Hepatic Encephalopathy
Not yet recruiting
Effect of Mini-Program Monitoring on Hepatic Encephalopathy in Post-TIPS Patients
Hepatic Encephalopathy, Liver Cirrhosis
Not yet recruitingPhase 4
Daridorexant for Sleep Disturbance in Adults With Liver Cirrhosis
Liver Cirrhosis, Sleep Disturbance
Not yet recruiting
Equivalence of Electronic vs Paper-based PHES in Diagnosing Hepatic Encephalopathy
Liver Cirrhosis, Hepatic Encephalopathy (HE)
Recruiting
4D-Flow MRI Assessment of Portal Hypertension and TIPS Outcomes in Cirrhosis
Cirrhosis, Portal Hypertension
Active, not recruitingPhase 1/2
RTX001 Autologous Engineered Macrophages for Liver Cirrhosis
End-stage Liver Disease (ESLD), Cirrhosis, Liver
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Dina Kao, MD principal investigator
Associate Professor
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing FMT in people with Hepatic Encephalopathy, run by University of Alberta at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Jun 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Portion of participants with normalization of ICT or Stroop Test during the study (time frame: 8 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03439982, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jun 2022.